Expertise in
34
conditions

Dr. Chandrakant V. Mehta

Rheumatology
Southland Arthritis And Osteoporosis
31515 Rancho Pueblo Rd, 
Temecula, CA 
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
34
conditions
Southland Arthritis And Osteoporosis
31515 Rancho Pueblo Rd, 
Temecula, CA 

Overview

Chandrakant Mehta is a Rheumatologist practicing medicine in Temecula, California.

Dr. Mehta is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Fibromyalgia, Osteoporosis, and Postmenopausal Osteoporosis.

Dr. Mehta is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, participating in 6 clinical trials. Dr. Mehta is currently accepting new patients.

Specialties

Rheumatology

Licenses

Specialist in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

Loma Linda University , Rheumatology , 1981 - 1983

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Southland Arthritis And Osteoporosis
31515 Rancho Pueblo Rd, Temecula, CA 92592
Other Locations
Southland Arthritis And Osteoporosis
1820 Fullerton Ave, Corona, CA 92881
Southland Arthritis And Osteoporosis
949 Calhoun Pl, Hemet, CA 92543

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required
Before you request

UC San Diego

200 W Arbor Dr, 
San Diego, CA 
 (50.2 miles away)
800-926-8273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kenneth Kalunian is a Rheumatologist practicing medicine in San Diego, California. Dr. Kalunian is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Cutaneous Lupus Erythematosus (CLE), Synovectomy, and Endoscopy.

Expertise in
3
conditions
Expertise in
3
conditions
Referral may be required
Before you request

Jennifer Moreno Department Of Veterans Affairs Medical Center

3350 La Jolla Village Dr, 
San Diego, CA 
 (42.3 miles away)
858-552-8585
Languages Spoken:
English

Robert Terkeltaub is a Rheumatologist practicing medicine in San Diego, California. Dr. Terkeltaub is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Gout, Arthritis, Calcium Pyrophosphate Arthritis, and Synovitis.

Expertise in
54
conditions
Dr. Samy K. Metyas
Rheumatology
Expertise in
54
conditions
Dr. Samy K. Metyas
Rheumatology
Referral may be required
Before you request

Metyas, Samy, M.D., Inc.

500 W San Bernardino Rd, 
Covina, CA 
 (61.9 miles away)
626-966-1909
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Samy Metyas is a Rheumatologist practicing medicine in Covina, California. Dr. Metyas is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Fibromyalgia, Rheumatoid Arthritis (RA), Osteoporosis, and Postmenopausal Osteoporosis. Dr. Metyas is board certified in American Board Of Internal Medicine. Dr. Metyas is currently accepting new patients.

Frequently Asked Questions about Dr. Chandrakant V. Mehta

How do I make an appointment with Dr. Chandrakant V. Mehta?

You can book an appointment with Dr. Chandrakant V. Mehta by calling their office at 951-303-1500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chandrakant V. Mehta a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chandrakant V. Mehta is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chandrakant V. Mehta specialize in?

While Dr. Chandrakant V. Mehta is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Fibromyalgia, and Osteoporosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Chandrakant V. Mehta accept my insurance?

Dr. Chandrakant V. Mehta accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 951-303-1500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehta's expertise for a condition
ConditionClose
    View All 30 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile